US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neuphoria Therapeutics Inc

6.87

-0.2800-3.92%

Post-market: 6.870.00000.00%19:44 EDT

Volume:30.70K

Turnover:216.49K

Market Cap:12.92M

PE:4.04K

High:7.35

Open:7.26

Low:6.67

Close:7.15

Loading ...

Overview Company News Filings

Neuphoria Therapeutics Q1 EPS $6.55 Up From $(2.83) YoY, Sales $15.00M

Neuphoria Provides First Quarter 2025 Business Updates

THOMSON REUTERS

BRIEF-Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026 - SEC Filing

Neuphoria Therapeutics Inc - Affirm-1 Phase 3 Trial of Bnc-210 Topline Readout Expected Q3 2025 - SEC Filing

THOMSON REUTERS

Neuphoria Therapeutics Inc - Cash Runway Extends Into Q3 2026 - SEC Filing

THOMSON REUTERS

Neuphoria Therapeutics Inc. Delays Q1 2025 Financial Report Due to Documentation Compilation Needs

BRIEF-Neuphoria Therapeutics Inc - Merck Pays $15M Milestone, Extends Cash Runway To Q3 2026

Neuphoria Therapeutics Inc - Merck Pays $15M Milestone, Extends Cash Runway to Q3 2026

THOMSON REUTERS

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

University of Nevada, Las Vegas Opens NuScale Power Energy Exploration (E2) Center™

Rensselaer Polytechnic Institute Opens NuScale Power Energy Exploration Center

BUZZ-Neuphoria Therapeutics rises on $15 mln milestone payment from Merck

Neuphoria Therapeutics to Receive $15 Mln Payment from Merck

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment From Merck

THOMSON REUTERS

Neuphoria Therapeutics Inc - Co Eligible for up to $450 Million in Additional Milestone Payments

THOMSON REUTERS

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

BRIEF-Neuphoria Therapeutics Files For Offer, Resale From Time To Time By Selling Shareholder Of Up To 1.1 Million Shares Of Common Stock

Neuphoria Therapeutics Files for Offer, Resale From Time to Time by Selling Shareholder of up to 1.1 Mln Shares of Common Stock

THOMSON REUTERS

Bionomics Strategic Shift with Neuphoria Redomiciliation

ADRs Advance; Neuphoria Therapeutics Inc. Climbs 118%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NEUP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEUP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEUP\",,,,,undefined,":{"symbol":"NEUP","market":"US","secType":"STK","nameCN":"Neuphoria Therapeutics Inc","latestPrice":6.87,"timestamp":1749240000000,"preClose":7.15,"halted":0,"volume":30698,"hourTrading":{"tag":"盘后","latestPrice":6.87,"preClose":6.87,"latestTime":"19:44 EDT","volume":52,"amount":356.54,"timestamp":1749253452930},"delay":0,"floatShares":846200,"shares":1879962,"eps":0.001699,"marketStatus":"Market Closed","change":-0.28,"latestTime":"06-06 16:00:00 EDT","open":7.26,"high":7.35,"low":6.6703,"amount":216492.334246,"amplitude":0.095063,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.001699,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.15,"postHourTrading":{"tag":"盘后","latestPrice":6.87,"preClose":6.87,"latestTime":"19:44 EDT","volume":52,"amount":356.54,"timestamp":1749253452930},"volumeRatio":1.247298015482588},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEUP\",,,,,undefined,":{"symbol":"NEUP","floatShares":846200,"roa":"-1.01%","roe":"25.45%","lyrEps":-0.008618,"volumeRatio":1.247298015482588,"shares":1879962,"dividePrice":0,"high":7.35,"amplitude":0.095063,"preClose":7.15,"low":6.6703,"week52Low":2.9,"pbRate":"0.50","psRate":"0.82","week52High":12.55,"institutionHeld":0.0927,"latestPrice":6.87,"eps":0.001699,"divideRate":0,"volume":30698,"delay":0,"ttmEps":0.001699,"open":7.26,"prevYearClose":3.43,"prevWeekClose":6.645,"prevMonthClose":6.645,"prevQuarterClose":5.76,"fiveDayClose":6.645,"twentyDayClose":4.94,"sixtyDayClose":4.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEUP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537462346","title":"Neuphoria Therapeutics Q1 EPS $6.55 Up From $(2.83) YoY, Sales $15.00M","url":"https://stock-news.laohu8.com/highlight/detail?id=2537462346","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537462346?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:27","pubTimestamp":1747772835,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly earnings of $6.55 per share. This is a 331.45 percent increase over losses of $(2.83) per share from the same period last year.  The company reported $15.00 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45530037/neuphoria-therapeutics-q1-eps-6-55-up-from-2-83-yoy-sales-15-00m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","LENZ"],"gpt_icon":0},{"id":"2537239746","title":"Neuphoria Provides First Quarter 2025 Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2537239746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537239746?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:22","pubTimestamp":1747772560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA2NFQDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2537623927","title":"BRIEF-Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623927","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623927?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:21","pubTimestamp":1747772488,"startTime":"0","endTime":"0","summary":"BRIEF-Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026 - SEC FilingMay 20  - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q3 2026 - SEC FILINGNEUPHORIA THERAPEUTICS INC - AFFIRM-1 PHASE 3 TRIAL OF BNC-210 TOPLINE READOUT EXPECTED Q3 2025 - SEC FILINGSource text: [ID:n0001213900-25-045970]Further company coverage: NEUP.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS1VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2537862364","title":"Neuphoria Therapeutics Inc - Affirm-1 Phase 3 Trial of Bnc-210 Topline Readout Expected Q3 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537862364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537862364?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:17","pubTimestamp":1747772267,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS1VZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2537623663","title":"Neuphoria Therapeutics Inc - Cash Runway Extends Into Q3 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623663?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:17","pubTimestamp":1747772267,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS1VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2535870518","title":"Neuphoria Therapeutics Inc. Delays Q1 2025 Financial Report Due to Documentation Compilation Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2535870518","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535870518?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:06","pubTimestamp":1747339562,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The company cited the need for additional time to compile and analyze supporting documentation and to allow its independent registered public accounting firm to complete its review. Neuphoria expects to file the report within the five-day extension period allowed under Rule 12b-25.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuphoria Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL2nm3ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2527414489","title":"BRIEF-Neuphoria Therapeutics Inc - Merck Pays $15M Milestone, Extends Cash Runway To Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2527414489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527414489?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:24","pubTimestamp":1744723464,"startTime":"0","endTime":"0","summary":"BRIEF-Neuphoria Therapeutics Inc - Merck Pays $15M Milestone, Extends Cash Runway To Q3 2026April 15 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA THERAPEUTICS INC - MERCK PAYS $15M MILESTON","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2527902684","title":"Neuphoria Therapeutics Inc - Merck Pays $15M Milestone, Extends Cash Runway to Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2527902684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527902684?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:02","pubTimestamp":1744718533,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2527416360","title":"Neuphoria Provides a Review of 2024 and Highlights 2025 Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2527416360","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527416360?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210. US $15M milestone payment from Merck extends company’s cash runway to Q3 2026. Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder  is progressing as planned with topline readout anticipated in Q3 2025. A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder  is planned to follow the read-out of the Phase 3 study in social anxiety disorder SAD.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuphoria-provides-review-2024-highlights-120000803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4081","PAM","BK4139","BK4563","NEUP"],"gpt_icon":0},{"id":"2524444827","title":"University of Nevada, Las Vegas Opens NuScale Power Energy Exploration (E2) Center™","url":"https://stock-news.laohu8.com/highlight/detail?id=2524444827","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524444827?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:30","pubTimestamp":1743625800,"startTime":"0","endTime":"0","summary":"NuScale’s E2 Center simulator to offer hands-on nuclear science and engineering learning opportunities. CORVALLIS, Ore., April 02, 2025----NuScale Power Corporation , the industry-leading provider of proprietary and innovative advanced small modular reactor nuclear technology, today announced the opening of its next Energy Exploration  Center at the University of Nevada, Las Vegas  to help support the development of a skilled nuclear-ready workforce. The E2 Center at UNLV was co-funded by a grant from the U.S. Department of Energy’s Nuclear Energy University Program .Founded in 2007, NuScale Power Corporation  is the industry-leading provider of proprietary and innovative advanced small modular reactor  nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/university-nevada-las-vegas-opens-203000625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4606","BK4139","BK4182","SMR","NEUP"],"gpt_icon":0},{"id":"2522700371","title":"Rensselaer Polytechnic Institute Opens NuScale Power Energy Exploration Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700371?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:15","pubTimestamp":1742847300,"startTime":"0","endTime":"0","summary":"Center to educate students on the importance of advanced nuclear technology with hands-on learning opportunities. Will allow students to practice simulated power plant operation scenarios, paving the way for the next generation of energy experts. NuScale E2 Centers are innovative learning environments that offer a hands-on opportunity to experience simulated, real-world nuclear power plant operation scenarios. Using state-of-the-art computer modeling within a 12-module control room simulator, the E2 Center will allow users at RPI to assume the role of control room operator, providing the chance to apply nuclear science and engineering principles and gain real-life experience. The E2 Center will also facilitate community education on the benefits of nuclear power through demonstrations and tours for local leaders, K-12 students and the broader public.To date, NuScale has unveiled eight E2 Centers with university partners, including RPI, Oregon State University , Texas A&M University , I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rensselaer-polytechnic-institute-opens-nuscale-201500130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NEUP","BK4182","SMR","BK4606","BK4139"],"gpt_icon":0},{"id":"2510091573","title":"BUZZ-Neuphoria Therapeutics rises on $15 mln milestone payment from Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2510091573","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510091573?lang=en_us&edition=fundamental","pubTime":"2025-02-12 23:50","pubTimestamp":1739375411,"startTime":"0","endTime":"0","summary":"BUZZ-Neuphoria Therapeutics rises on $15 mln milestone payment from Merck ** Massachusetts-based drug developer Neuphoria Therapeutics NEUP.O rises 3.31% to $4.65 in morning trade ** Co, which develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nL4N3P31CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU1037948897.HKD","LU1941712348.USD","LU0006306889.USD","IE0002141913.USD","MRK","SG9999014567.USD","SG9999014575.USD","LU1057294990.SGD","LU1061106388.HKD","LU1430594728.SGD","BK4516","LU2106854487.HKD","SG9999014559.SGD","LU1116320901.HKD","SG9999015358.SGD","LU0238689110.USD","LU2361045086.USD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU0122379950.USD","IE00BLSP4239.USD","LU1069347547.HKD","LU2324357040.USD","IE00BLSP4452.SGD","LU1934455277.USD","LU1066053197.SGD","LU1585245621.USD","LU0320765489.SGD","LU2461242641.AUD","LU0289739699.SGD","SG9999014542.SGD","IE0009355771.USD","LU0058720904.USD","LU1941712264.USD","LU1066051225.USD","LU2023250504.SGD","LU0203345920.USD","LU0265550359.USD","LU0234572021.USD","LU1023059063.AUD","LU2468319806.SGD","LU1699723380.USD","IE00B4R5TH58.HKD","LU1291159041.SGD","NEUP","LU0985320562.USD","LU0203347892.USD"],"gpt_icon":0},{"id":"2510269375","title":"Neuphoria Therapeutics to Receive $15 Mln Payment from Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2510269375","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510269375?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:34","pubTimestamp":1739363640,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.The biotechnology company said Wednesday that it is expecting to receive $15 million from the pharmaceutical giant now that it has started the phase 2 clinical trial to evaluate the safety and efficacy of MK-1167.The drug aims to enhance the activity of a certain receptor in the brain which is involved in cognitive functions like memory and learning.Neuphoria said that the payment marks the second milestone payment in collaboration with Merck. The company has an agreement to receive $450 million in additional milestone payments for progress on multiple candidates, including MK-1167.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LU0203345920.USD","BK4559","BK4516","LU1585245621.USD","IE0009355771.USD","SG9999014575.USD","IE00B4R5TH58.HKD","MRK","SG9999002224.SGD","LU0234572021.USD","LU2324357040.USD","LU0070302665.USD","LU0861579265.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU0208291251.USD","SG9999014559.SGD","IE00BSNM7G36.USD","LU0122379950.USD","LU2361044865.SGD","LU0965508806.USD","LU2468319806.SGD","LU2361044949.HKD","LU1989772840.SGD","LU1066051498.USD","SG9999001440.SGD","SG9999001176.USD","LU0289739699.SGD","LU1983299246.USD","LU1116320737.USD","LU1934455277.USD","LU0058720904.USD","LU1162221912.USD","LU0238689110.USD","LU1035773651.USD","LU1066053197.SGD","NEUP","LU0006306889.USD","SGXZ57979304.SGD","LU1093756168.USD","LU1934455194.USD","LU0265550359.USD","LU1023059063.AUD","LU2023250843.SGD","IE00B2B36J28.USD","LU1571399168.USD","SG9999002232.USD","IE00BJT1NW94.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2510378967","title":"Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment From Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2510378967","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510378967?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA8RL1VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"2510373488","title":"Neuphoria Therapeutics Inc - Co Eligible for up to $450 Million in Additional Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2510373488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510373488?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA8RL1VT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","LU1066051225.USD","LU2461242641.AUD","MRK","IE00BBT3K403.USD","LU1116320737.USD","LU1585245621.USD","LU0265550946.USD","LU0289739699.SGD","LU0965508806.USD","LU2324357040.USD","LU2112291526.USD","LU1989772840.SGD","LU0965509010.AUD","SG9999015341.SGD","LU1093756168.USD","BK4559","BK4585","LU2361045086.USD","LU2023250504.SGD","SG9999001440.SGD","IE000M9KFDE8.USD","LU1430594728.SGD","SG9999001176.SGD","IE00BLSP4452.SGD","IE00B2B36J28.USD","LU1941712264.USD","LU0211331839.USD","LU1037948541.HKD","LU1929549753.HKD","LU0070302665.USD","LU1037948897.HKD","LU1934455863.HKD","LU0985320562.USD","SG9999014542.SGD","LU1699723380.USD","LU1941712348.USD","LU0106261372.USD","LU2089984988.USD","IE00BLSP4239.USD","LU1934455194.USD","SG9999001176.USD","LU2361044949.HKD","LU1066051498.USD","BK4139","NEUP","LU1917777945.USD","LU1069347547.HKD","LU0234572021.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2510475378","title":"Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2510475378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510475378?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361600,"startTime":"0","endTime":"0","summary":"Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator. BURLINGTON, Mass., Feb. 12, 2025  -- Neuphoria Therapeutics Inc.  , a late-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients’ lives, announced today that the Company is due to receive a $15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator , for the treatment of the symptoms of Alzheimer’s disease dementia .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuphoria-therapeutics-inc-receive-15m-120000470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU0203345920.USD","LU2023250843.SGD","SG9999014542.SGD","LU1571399168.USD","BK4563","LU1093756168.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU1023059063.AUD","NEUP","SG9999001176.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","BK4588","LU1066051498.USD","LU1037948541.HKD","PAM","BK4559","LU0208291251.USD","LU2468319806.SGD","SG9999014559.SGD","LU1162221912.USD","LU1066051225.USD","LU2106854487.HKD","LU2361045086.USD","MRK","LU1934455863.HKD","LU1069347547.HKD","LU1066051811.HKD","LU1093756325.SGD","LU1430594728.SGD","IE000M9KFDE8.USD","LU1989772840.SGD","LU0234572021.USD","LU0320765489.SGD","SG9999002232.USD","SG9999015358.SGD","LU0006306889.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0985320562.USD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU1116320737.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU2361044949.HKD","LU0203347892.USD","LU0965508806.USD"],"gpt_icon":0},{"id":"2506030483","title":"BRIEF-Neuphoria Therapeutics Files For Offer, Resale From Time To Time By Selling Shareholder Of Up To 1.1 Million Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2506030483","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506030483?lang=en_us&edition=fundamental","pubTime":"2025-01-28 00:14","pubTimestamp":1737994453,"startTime":"0","endTime":"0","summary":"BRIEF-Neuphoria Therapeutics Files For Offer, Resale From Time To Time By Selling Shareholder Of Up To 1.1 Million Shares Of Common StockJan 27  - Neuphoria Therapeutics Inc NEUP.O:NEUPHORIA THERAPEUTICS FILES FOR OFFER, RESALE FROM TIME TO TIME BY SELLING SHAREHOLDER OF UP TO 1.1 MILLION SHARES OF COMMON STOCKSource text: [ID:n0001213900-25-006517]Further company coverage: NEUP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON0C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2506437074","title":"Neuphoria Therapeutics Files for Offer, Resale From Time to Time by Selling Shareholder of up to 1.1 Mln Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2506437074","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506437074?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:26","pubTimestamp":1737987980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON0C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEUP","BK4139"],"gpt_icon":0},{"id":"2494102568","title":"Bionomics Strategic Shift with Neuphoria Redomiciliation","url":"https://stock-news.laohu8.com/highlight/detail?id=2494102568","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494102568?lang=en_us&edition=fundamental","pubTime":"2024-12-25 06:49","pubTimestamp":1735080592,"startTime":"0","endTime":"0","summary":"Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Neuphoria Therapeutics Inc. has completed its redomiciliation, transferring governance from Bionomics’ organizational documents to Neuphoria’s new Certificate of Incorporation and bylaws. This strategic move positions Neuphoria as the successor issuer to Bionomics, with its shares now registered under the Exchange Act, which may influence its governance structure and shareholder rights.Find detailed analytics on BNOX stock on TipRanks’ Stock Analysis page.Ford  Electric Vehicles May Have Tougher Chassis Soon","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bionomics-strategic-shift-neuphoria-redomiciliation-224952111.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bionomics-strategic-shift-neuphoria-redomiciliation-224952111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","BK4141","LU1894683348.USD","LU0640476718.USD","LU0011850046.USD","LU0708994859.HKD","BK4585","LU1280957306.USD","BK4550","BK4561","F","LU0061475181.USD","SG9999015945.SGD","LU0320765489.SGD","LU1267930573.SGD","BK4574","BK4535","BK4555","BK4099","BK4602","BK4524","LU0128525929.USD","BK4551","LU0321505439.SGD","BK4527","BK4579","LU0786609619.USD","BK4575","LU1894683264.USD","BK4516","BK4534","BK4512","SG9999015978.USD","SG9999015952.SGD","LU0081259029.USD","LU0029864427.USD","NEUP","LU0321505868.SGD","BK4108","LU0310800379.SGD","BK4554","LU0208291251.USD","BNOX","LU0070302665.USD","BK4515","SG9999015986.USD","BK4139","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2494051805","title":"ADRs Advance; Neuphoria Therapeutics Inc. Climbs 118%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494051805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494051805?lang=en_us&edition=fundamental","pubTime":"2024-12-25 05:30","pubTimestamp":1735075800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Tuesday, as the S&P/BNY Mellon index of American depositary receipts increased 0.2% to 180.47.The European index added 0.3% to 163.07. The Asian index increased 0.1% to 237.13. The Latin American index rose 0.8% to 176.46, while the emerging-markets index was flat at 384.73.Australia's Neuphoria Therapeutics Inc. was the biggest leader during the session, rocketing 118% to $6.63, and Israel-based SaverOne 2014 Ltd. soared 63% to $1.58. Foresight Autonomous Holdings Ltd., which is based in Israel, rounded out the top three leaders on Tuesday, with shares rocketing 41% to $2.41.uCloudlink Group Inc., based in Hong Kong, posted the largest decline, plunging 14% to $1.79, followed by shares of China's Huize Holding Ltd., which plunged 11% to $3.40. Shares of China-based Akso Health Group plunged 11% to $1.11.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEUP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-24","symbol":"NEUP","defaultRemindTime":1735050600000,"type":"split","dateTimestamp":1735016400000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEUP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NEUP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1695960000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NEUP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NEUP","date":"2025-06-06","current":2.306801,"percent":0.990909,"low":-2152.911097,"twenty":-1.112407,"median":-1.056786,"eighty":-0.536694,"high":2.306801,"avg":-74.05853,"sd":320.04842,"marketCap":13441728},"quantilePoints":[{"date":"2024-12-27","current":-1445.015744,"twenty":-2011.332026,"median":-1798.963421,"eighty":-1586.594815,"marketCap":15641406744},{"date":"2025-01-03","current":-951.437333,"twenty":-1445.015744,"median":-1245.311321,"eighty":-1113.798652,"marketCap":10298723991},{"date":"2025-01-10","current":-0.484092,"twenty":-1335.908938,"median":-1032.617992,"eighty":-0.531583,"marketCap":5240001},{"date":"2025-01-17","current":-0.452507,"twenty":-1207.318772,"median":-0.536694,"eighty":-0.48107,"marketCap":4898109},{"date":"2025-01-24","current":-0.524667,"twenty":-1141.075354,"median":-0.511137,"eighty":-0.48107,"marketCap":5679203},{"date":"2025-01-31","current":-0.81331,"twenty":-1016.381861,"median":-0.554735,"eighty":-0.482883,"marketCap":8803579},{"date":"2025-02-07","current":-0.757686,"twenty":-381.062919,"median":-0.702062,"eighty":-0.484985,"marketCap":8201486},{"date":"2025-02-14","current":-0.691539,"twenty":-0.803388,"median":-0.699056,"eighty":-0.486483,"marketCap":7485483},{"date":"2025-02-21","current":-1.080318,"twenty":-1.103422,"median":-0.706573,"eighty":-0.495533,"marketCap":8872986},{"date":"2025-02-28","current":-1.110267,"twenty":-1.105989,"median":-0.757686,"eighty":-0.509378,"marketCap":9118970},{"date":"2025-03-07","current":-1.180862,"twenty":-1.111551,"median":-0.770464,"eighty":-0.516549,"marketCap":9698789},{"date":"2025-03-14","current":-1.035394,"twenty":-1.111551,"median":-0.796773,"eighty":-0.529478,"marketCap":8504010},{"date":"2025-03-21","current":-1.108128,"twenty":-1.110267,"median":-1.022558,"eighty":-0.551126,"marketCap":9101399},{"date":"2025-03-28","current":-1.240761,"twenty":-1.1415,"median":-1.048229,"eighty":-0.607653,"marketCap":10190756},{"date":"2025-04-04","current":-1.210812,"twenty":-1.180862,"median":-1.055716,"eighty":-0.664779,"marketCap":9944772},{"date":"2025-04-11","current":-1.048229,"twenty":-1.179151,"median":-1.052508,"eighty":-0.679813,"marketCap":8609432},{"date":"2025-04-17","current":-1.093153,"twenty":-1.172305,"median":-1.056786,"eighty":-0.692441,"marketCap":8978407},{"date":"2025-04-25","current":-1.110267,"twenty":-1.154335,"median":-1.064274,"eighty":-0.697252,"marketCap":9118970},{"date":"2025-05-02","current":-1.069622,"twenty":-1.152624,"median":-1.071761,"eighty":-0.702663,"marketCap":8785135},{"date":"2025-05-09","current":-1.056786,"twenty":-1.146207,"median":-1.070692,"eighty":-0.70567,"marketCap":8679713},{"date":"2025-05-16","current":-1.014001,"twenty":-1.12567,"median":-1.069622,"eighty":-0.714089,"marketCap":8328307},{"date":"2025-05-23","current":1.878545,"twenty":-1.12567,"median":-1.066199,"eighty":-0.70567,"marketCap":10946278},{"date":"2025-05-30","current":2.090639,"twenty":-1.118824,"median":-1.058925,"eighty":-0.691539,"marketCap":12182153},{"date":"2025-06-06","current":2.306801,"twenty":-1.112407,"median":-1.056786,"eighty":-0.536694,"marketCap":13441728}],"updateTime":1749377313798}}}